• Home
  •  / Lophius Biosciences

Lophius Biosciences

OverviewSuggest Edit

Lophius Biosciences is a biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.
The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. 
With its T-Track CMV leading product, based on T-activation technology, Lophius offers a sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

TypePrivate
Founded2002
HQRegensburg, DEMap
Websitelophius.com
View Jobs

Locations

Lophius Biosciences is headquartered in
Regensburg, Germany

Location Map
All Locations (1)

Latest Updates

Employees (est.) (Nov 2021)3(-25%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Lophius Biosciences

Bernd Merkl

Bernd Merkl

Chief Executive Officer (CEO) / Managing Director
Ludwig Deml

Ludwig Deml

Chief Scientific Officer (CSO)
Ralf Wagner

Ralf Wagner

Chairman of the Board (COB)
Show more

Lophius Biosciences Office Locations

Lophius Biosciences has an office in Regensburg
Regensburg, DE (HQ)
13 Am Biopark
Show all (1)

Lophius Biosciences Financials and Metrics

Summary Metrics

Founding Date

2002

Lophius Biosciences total Funding

$14.4 m

Lophius Biosciences latest funding size

$2.36 m

Time since last funding

5 years ago

Lophius Biosciences investors

Bayern Kapital, Heidelberg Innovation, S-Refit, Bavarian Growth Fund, wolf biotech gmbh, VRD GmbH, WIC, BACH Wirtschafts-Consulting
Lophius Biosciences's latest funding round in March 2017 was reported to be $2.4 m. In total, Lophius Biosciences has raised $14.4 m
Show all financial metrics

Lophius Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Lophius Biosciences Online and Social Media Presence

Lophius Biosciences's Trends

Embed Graph

 Lophius Biosciences Frequently Asked Questions

  • When was Lophius Biosciences founded?

    Lophius Biosciences was founded in 2002.

  • Who are Lophius Biosciences key executives?

    Lophius Biosciences's key executives are Bernd Merkl, Ludwig Deml and Ralf Wagner.

  • How many employees does Lophius Biosciences have?

    Lophius Biosciences has 3 employees.

  • Who are Lophius Biosciences competitors?

    Competitors of Lophius Biosciences include Genclis, ECM Therapeutics and Sanesco.

  • Where is Lophius Biosciences headquarters?

    Lophius Biosciences headquarters is located at 13 Am Biopark, Regensburg.

  • Where are Lophius Biosciences offices?

    Lophius Biosciences has an office in Regensburg.

  • How many offices does Lophius Biosciences have?

    Lophius Biosciences has 1 office.